Groups of λlacZ transgenic mice were treated i.p. with Nnitrosodimethylamine (NDMA) as single doses of 5 mg/kg or 10 mg/kg or as 10 daily doses of 1 mg/kg and changes in DNA N7-or O 6 -methylguanine or the repair enzyme O 6 -alkylguanine-DNA alkyltransferase (AGT) were followed for up to 14 days in various tissues. Adduct induction in the liver exceeded by at least one order of magnitude than observed in the next nearest target tissue (lung), and was approximately linearly related to dose, except for O 6 -methylguanine after the first dose of 1 mg/kg which was lower than expected. Substantial induction of λlacZ mutagenesis was observed only in the liver, where the mutant frequency was already maximal within 7 days after 5 mg/ kg NDMA and remained unchanged thereafter up to 49 days. Small but marginally significant increases in mutant frequency were consistently observed in the spleen after all three modes of treatment. A lack of proportionality between mutation induction and the administered dose or the corresponding adduct levels was observed, probably reflecting the importance of toxicity-related cell proliferation caused by NDMA at higher doses. Twenty eight days after a dose of 10 mg/kg (causing a 3.6-fold increase in mutant frequency), NDMA was found to increase the frequency of GC→AT mutations (with a concomitant shift of their preferential location from CpG sites to GpG sites), which made up~60% of the induced mutations. Surprisingly, NDMA also caused a significant increase in deletions of a few (up to 11) base-pairs (22%).
Introduction
N-Nitrosodimethylamine (NDMA*) is a carcinogen of substantial laboratory and environmental interest, capable of inducing benign and malignant tumours in many animal species and in a variety of tissues, including the liver, the kidney, the lung and the nasal cavity (1, 2) . Human exposure to NDMA is widespread, associated primarily with nitrate-or nitrite-treated foods, certain beverages and tobacco smoke (3, 4) . Significant human exposure is also derived from endogenous formation of NDMA in the stomach and possibly in other body compart-ments (5) (6) (7) (8) . Accurate, direct estimation of endogenous exposure to NDMA is not possible, but, based on indirect evidence, it has been suggested that this mode of exposure may greatly exceed that arising from exogenous sources and may constitute a significant cancer risk factor for man (9, 10) . Although epidemiological studies have provided evidence compatible with a carcinogenic role of NDMA in man, such evidence is far from conclusive, possibly because the effectiveness of these studies was compromised by the difficulty of estimating the true extent of total NDMA exposure (11) (12) (13) (14) (15) (16) (17) (18) . Hence, and in view of the powerful and multispecies animal carcinogenicity of NDMA, there is a need to add mechanism-based approaches to epidemiological investigations of the role of NDMA in human cancer.
NDMA has been widely employed as a model experimental carcinogen and for this reason much is known about the mechanism of its biological effects. It is metabolised primarily in the liver by cytochrome P4502E1 to a methylating reactive intermediate (probably the methyldiazonium ion) which methylates cellular macromolecules (19) . It is an S N 1-type methylating agent, generating in DNA primarily N7-methylguanine (N7-meG,~70% of all adducts formed), O 6 -methylguanine (O 6 -meG,~7%), N3-methyladenine (~3%), O 4 methylthymine (O 4 -meT Ͻ0.1%), methylphosphotriesters (~12%) as well as a number of other minor base modifications (20) . The quantitatively major DNA lesion N7-meG is not directly mutagenic, but it can undergo enzymatic or spontaneous depurination to form mutagenic apurinic sites (21) . On the other hand, oxygen-centred base methylation adducts are directly mutagenic and most current evidence suggests that the most abundant of these, O 6 -meG, plays a major role in mutagenesis and carcinogenesis by NDMA and other S N 1-type methylating agents. This is supported by correlations between the accumulation of O 6 -meG in different animal tissues or cell types and susceptibility to methylating-agent carcinogenesis, as well as by the cancer protective effect of the repair enzyme O 6 -alkylguanine-DNA alkyltransferase (AGT) which specifically repairs O 6 -meG (22) (23) (24) (25) .
Single-adduct studies have demonstrated that O 6 -meG is strongly premutagenic, giving rise to GC→AT transitions by direct miscoding during cell replication (26) (27) (28) , a sequence change which has been found to dominate the mutation spectra induced in vitro and in vivo by S N 1 methylating agents (29) (30) (31) . In the case of NDMA, sequence analysis of large numbers of mutants derived from mutagenesis in the lacI gene of Escherichia coli has shown that it induces predominantly GC→AT transitions, as well as a small proportion (~10%) of other types of mutations (30, 32) .
While information on the mutagenicity of NDMA in whole animals is relatively limited, recent studies with lacZ or lacI transgenic mice have shown that it is mutagenic mainly in the liver and, to a smaller degree, the lung and kidney, but not in the bone marrow, urinary bladder or testis (33) (34) (35) . Furthermore, it has recently been reported that administration of NDMA in the form of split doses or even chronic treatment in the drinking water is more effective in inducing liver mutations than administration of the same amount as a single dose (33, 36) . However, as no DNA adduct data were reported in these studies, interpretation of dose effects and extrapolation to events likely to occur under environmentally relevant conditions is difficult. As regards the types of mutations induced by NDMA in vivo, limited information comes from Mirsalis et al. (35) who reported that eight out of 10 liver mutations induced in lacI transgenic mice by five daily doses of 4 mg/kg NDMA were GC→AT transitions.
GC→AT mutations have also been found to occur frequently in cancer-related genes of animal tumours induced by NDMA and other methylating N-nitroso compounds (37) (38) (39) (40) (41) (42) (43) , thus implying an important role for O 6 -meG in carcinogenesis by such agents. On the other hand, it is notable that in a number of cases human cancers for which, on the basis of epidemiological studies, the etiological involvement of Nnitroso compounds (including NDMA) is suspected, the mutations in the corresponding genes are not dominated by GC→AT transitions (44) (45) (46) (47) . Although these observations may indicate lack of involvement of NDMA in tumour induction, they also invoke the possibility that under certain conditions NDMA may induce a more complex pattern of mutations than that observed under the conditions employed in experimental studies.
In the work reported here an attempt was made to begin addressing the question of the mechanism of NDMA mutagenesis in vivo. For this purpose, λlacZ transgenic mice were exposed to single or multiple doses of NDMA and the kinetics of induction of DNA methylation adducts and mutations in different tissues, as well as the spectrum of induced mutations, examined. We report that, following single or multiple treatment of animals with NDMA with doses ranging up to 10 mg/kg, (i) a clear mutagenic effect was observed only in the liver, while a small effect was consistently observed in the spleen, (ii) as the dose was increased, liver mutagenesis increased more than adduct accumulation and (iii) after a dose of 10 mg/kg NDMA, in addition to the predominating GC→AT mutations a significant proportion of single-and multiple-base deletions were also induced in the liver.
Materials and methods

Animal experiments
Male Muta TM mice, 9-10 weeks old (Hazleton) were maintained on normal laboratory chow. For each dose or time point, groups of four animals were treated i.p. with NDMA dissolved in physiological saline. Animals were killed at appropriate times after treatment and tissues immediately placed in liquid nitrogen. For AGT measurement in white blood cells, the cells were isolated from fresh blood by lysis of the erythrocytes in 155 mM NH 4 Cl/10 mM KHCO 3 /0.1 mM EDTA on ice for 15 min, followed by centrifugation and washing of the leukocyte pellet with PBS, prior to freezing. All tissues were stored at -70 o C until analysis.
Measurement of O 6 -meG, N7-meG and AGT
DNA was isolated by a previously reported method involving multiple treatments with proteinase K and RNase and phenol/chloroform extraction (48) . Measurement of O 6 -meG was carried out by the competitive repair assay (49), with a limit of detection, using 10 µg DNA per assay, of 0.05 fmol/µg DNA (0.08 µmol/molG). N7-meG was analysed by hydrolysis of DNA (enzymatic or by heat treatment) prior to HPLC with electrochemical detection or by immunoslot-blot methodology using monoclonal antibodies, with a limit of detection of 0.6 fmol/µg DNA (1 µmol/molG) (50). AGT was determined in tissue extracts using as substrate 3 H-methylated calf thymus DNA (48) .
Mutant frequency analysis
λ Phages containing the lacZ gene were rescued from high molecular weight DNA using a commercially available phage packaging extract (Giga-pack II Gold, Stratagene) and subsequently used to infect E.coli lacZgalE bacteria (51) . Bacteria containing lacZ-mutated phages were selected using phenyl-β-galactoside (P-gal). In most cases Ͼ400 000 phages were analysed, while groups of four animals were used for each time-point.
Sequencing of mutants
To determine the region (α, β, ω) of the β-galactosidase gene in which the mutation was located, a β-galactosidase protein complementation assay was carried out involving replating of the mutants on the three complementation strains of E.coli: DH5a (α-, βϩ, ωϩ), W4680 (αϩ, β-, ωϩ) and Hfr3000ϫ90 (αϩ, βϩ, ω-) (52). The region thus determined to contain the mutations was subjected to PCR amplification using pairs of primers of which one was 5Ј-biotinylated. Following separation of PCR products by low melting agarose gel electrophoresis, binding of the biotinylated PCR products to magnetic beads and DNA sequence analysis was performed by standard methods (53) .
Results
In order to assess the dose-and time-relationships between DNA adduct formation and mutagenesis by NDMA, λlacZ transgenic mice were treated with single or multiple doses and adducts and mutations measured at various times. Attention was focused mainly on the liver and lung (known targets for NDMA carcinogenesis), as well as the spleen and the bone marrow in view of the high proliferation rate of these tissues. Additional tissues in which adducts were measured include white blood cells (WBC) and the brain.
DNA adducts. The kinetics of adduct formation and repair was examined in animals treated with single doses of 5 mg/kg or 10 mg/kg NDMA. As can be seen in Figures 1 and 2 , the liver showed by far the highest adduct levels, followed by the lung, spleen, WBC, bone marrow and brain. Six h after treatment with 5 mg/kg, the levels of O 6 -and N7-meG had already reached maximal values, thereafter decreasing with half-lives of 20-25 h and 35-55 h, respectively, depending on the tissue. Whereas no O 6 -meG could be detected 7 days after treatment, the more slowly repaired adduct N7-meG was still detectable in liver DNA at levels substantially higher than background even 14 days post-treatment. Significant depletion of AGT was observed 6 h after treatment in all tissues examined, followed by slow return to full activity within 7-14 days.
Animals were also treated with multiple doses of NDMA, consisting of 1 mg/kg NDMA every 24 h for 10 days. Tissues were collected 6 h after the 1st, 6th and 10th treatments, and DNA adducts and AGT measured. As can be seen in Figure 3 , the tissue distribution of adducts was similar to that seen after single doses, with the liver showing at least one order of magnitude higher adduct accumulation than the lung and the other tissues. In the liver, WBC and spleen, adducts approached steady-state levels by day 10. Although no O 6 -meG could be detected in the bone marrow and brain at any time point examined, significant AGT depletion was observed in these tissues, implying that O 6 -meG accumulation at levels below the detection limit had probably occurred.
Mutant frequencies. Mutant frequencies were measured in the liver, lung, spleen and bone marrow 7, 14, 28 and 49 days after 5 mg/kg NDMA and 14 and 28 days after 10 mg/kg NDMA. As can be seen in Table I , after 5 mg/kg NDMA a significant increase in MF occurred in the liver, where the MF had doubled by day 7 and remained practically unchanged until day 49. A small but statistically significant (p ϭ 0.037) increase also occurred in the spleen 7 days after treatment. An analogous picture was obtained after 10 mg/kg NDMA (Table II) , with the MF increasing substantially in the liver, where it almost quadrupled after 14 days and remained constant up to 28 days, and to a smaller but statistically significant degree (p ϭ 0.008) in the spleen 28 days post-treatment. No evidence of an increase in the MF was obtained for the bone marrow and lung. Mutant frequencies were also measured 14 and 28 days (29) 33 (11) 54 (7) 40 (6) 14 102 (24) 32 (7) 58 (9) 35 (6) 28 137 a (33) 31 (10) 64 (8) 69 (26) Data from 4 mice; two controls were analysed on day 14 and two on day 28. For experimental details, see Materials and methods. a p Ͻ 0.05 (t-test).
after completion of the 10-day treatment with 1 mg/kg/day NDMA (Table III ). An increase was observed in the liver, which became significant (p ϭ 0.019) 28 days post-treatment.
As was the case after single doses, a small (1.7-fold) increase was observed in the spleen on day 28. This increase is significant (p ϭ 0.029) when compared with the day 14 value, although it just failed to reach statistical significance when compared to the control animal value (p ϭ 0.06).
Sequence-characterisation of mutations
Spontaneous mutations. Fourty-three mutant plaques obtained from the livers of four control mice were selected at random and sequence-characterised. In four of these mutants, multiple mutations were observed. One mutation (a -C deletion at nucleotide position 109) was observed twice. Of the 47 mutations thus analysed, the majority (70%) consisted of single-base substitutions, including 41% transitions and 29% transversions (Tables IV and V) . The most frequent type of mutation was GC→AT transitions (28%), including 5/13 at CpG and 4/13 at GpG dinucleotides. In addition, all possible single-base substitutions were observed, as well as eight singlebase deletions, two single-base insertions, two large deletions and one three-base pair insertion.
Mutations in NDMA-treated mice. Fourty-three randomly selected mutants obtained from the livers of four mice 28 days after treatment with 10 mg/kg NDMA were sequenced. In four cases, multiple mutations were found. Of the 47 mutations thus analysed, 64% were single-base substitutions, consisting predominantly of transitions (58%) and a few transversions (6%) ( Tables V and VI) . In addition, seven single-base deletions, one single-base insertion, eight larger deletions of 4-100-bases and one 5-base insertion were found. Taking into account that these mutants were derived from a treatment which caused a 3.6-fold increase in MF relative to the controls, the observed mutation spectrum was corrected for the probable contribution of spontaneous mutations (Table V) . The only types of mutations in the calculated net mutation spectrum which were significantly (χ 2 test) increased were GC→AT transitions and single or multiple base deletions.
Discussion
In this study, quantitative and qualitative data on the induction by NDMA of methylated DNA adducts and gene mutations in λlacZ transgenic mice have been obtained. The liver was the main target for adduct induction, accumulating~10-30 times more adducts than the lung (tissue with the next most abundant adducts). The liver was also the primary target for mutagenesis. Single doses of 5 mg/kg or 10 mg/kg NDMA resulted in clear increases in liver MF within 7 days, with no Fourteen days post-treatment, N7-meG was still detectable in liver DNA at levels (20.3 fmol/µg DNA) which were greatly reduced but still significantly higher than in control animals. Based on the observed rate of loss of N7-meG, the levels of this adduct in liver DNA 28 days post-treatment are likely to have been of the order of 1 fmol/µg, comparable to that observed in the liver of untreated animals ( Figure 1 ). Table VII shows that the yield of liver adducts per unit dose (mg/kg NDMA) 6 h after treatment with 5 mg/kg or 10 mg/ kg NDMA is constant, whereas it is significantly reduced after a dose of 1 mg/kg. While adduct levels at a specific timepoint constitute a useful measure of the amount of the genotoxic damage occurring after a given dose, a more satisfactory quantitative measure of the biologically effective extent of DNA damage occurring in a given tissue would be provided by the area under the corresponding adducts-time curve. Calculation of the areas under the curve over the period 0-14 days after 5 mg/kg shows that, for different tissues, they correlate closely with the corresponding 6 h levels for both O 6 -and N7-meG (r 2 ϭ 1.00; p ഛ 0.01) (results not shown), indicating that the 6 h measurements reflect accurately the area under the curve over a wide range of tissue-specific adduct concentrations and repair capacities. Given that almost complete depletion of AGT was observed after both 5 mg/kg and 10 mg/kg NDMA, it is likely that the same correlation holds for the dose of 10 mg/kg NDMA (for which the available data do not permit the direct calculation of the corresponding areas under the adducts curve). Thus, the time-integrated concentration of the two major DNA adducts appears to be linearly related to the administered NDMA dose in the 5-10 mg/kg range. In contrast, the corresponding MF 14 or 28 days post-treatment shows clearly superlinear relationships with the dose (p for linearity Ͼ0.12) and the 6 h adduct levels (Table VII) . Characteristically, the number of net induced mutants (post-NDMA minus spontaneous) 28 days after 10 mg/ kg was 148 per 10 6 pfu, Ͼ3-fold greater than that induced by 5 mg/kg (47 per 10 6 pfu). This greater than linear increase of MF is likely to be the result of increased liver cell proliferation caused by the hepatotoxicity of 10 mg/kg NDMA (33, (54) (55) (56) . During 10 daily administrations of 1 mg/kg NDMA, O 6 -and N7-meG accumulated steadily in liver DNA, their 6 h adduct levels approaching a constant value by the end of this treatment period. Consequently the biologically effective concentration of each adduct throughout the dosing period, as reflected by the area under the curve, cannot be accurately estimated from the available data, since following each administration of NDMA there would have occurred a rapid increase in adduct levels followed by repair. However, the less extensive depletion of AGT and the consequent lower yield of O 6 -meG per unit dose caused by 1 mg/kg NDMA (Figure 3) imply that the area under the adducts curve for O 6 -meG during the split-dose regimen was less than that following a single administration of 10 mg/kg. As shown in Table VII , 28 days after the end of the split-dose regimen the net induced MF in the liver was 73 per 10 6 pfu, less than half of that caused by the same total dose of 10 mg/kg administered at once. Since no significant decrease in MF occurred up to 49 days after 5 mg/kg NDMA, the lower mutagenic efficiency of split dosing cannot be attributed to mutant loss, but was probably related to the lower effective concentration of O 6 -meG and the more limited toxicity-induced cell proliferation. While no systematic study of the effects of dose and time on toxicity-induced cell proliferation has been reported, it is noted that treatment of C3H mice with NDMA dissolved in their drinking water at a concentration of 30 ppm (resulting in a daily dose of~5 mg/ kg) for 16 days gave rise to a significant increase in hepatocyte proliferation, whereas no increase was observed in animals exposed to 3-fold lower concentration of NDMA (57) . Furthermore, Doolittle et al. (54) reported that seven daily treatments of CD-1 mice with 4 mg/kg NDMA gave rise to a toxicityassociated increase in hepatocyte replication, whereas a similar treatment with 2 mg/kg had no detectable effect. Finally, Suzuki et al. (33) recently reported that five daily oral doses of 1 mg/kg NDMA did not induce any significant cell proliferation in hepatocytes of Big Blue (C57Bl/C6) mice. Based on these data, it appears that little if any hepatocyte proliferation would be induced by 10 daily doses of 1 mg/kg NDMA as employed in our study, whereas it would have been after the highest single dose employed, i.e. 10 mg/kg.
Our finding that 10 mg/kg NDMA is more effective in inducing liver mutations when administered as a single dose than when split over 10 days contrasts with the recent report of Suzuki et al. (33) who reported that five daily doses of 1 mg/kg NDMA were more mutagenic in the liver of 8-week old male Big Blue mice than a single dose of 5 mg/kg. In view of the similarity in mouse strain (except for the transgene genotype), age and sex employed in that study and ours, this difference is unexpected and we have no satisfactory explanation for it, other than speculate that the more extended period of exposure in our study may have resulted in different 
cell replication kinetics in specific subpopulations of liver cells which constitute targets for NDMA mutagenesis (58) . We note, in this respect, that Mirsalis et al. (35) failed to induce mutations after five daily treatments of 2 mg/kg NDMA in 6-week old lacI mice, although they did report a positive response in 3-week old mice given the same dosage. An additional point of contrast of our results with those of Suzuki et al. (33) concerns our failure to observe induction of lung mutations by NDMA. On the other hand, in agreement with these authors, we too observed no NDMA-induced mutagenesis in the bone marrow. The levels of O 6 -meG in this tissue after 10 mg/kg NDMA were~200-fold lower than in the liver (Figure 2 ) while they were below the limit of detection after 10 daily doses of 1 mg/kg ( Figure 3 ). While NDMA causes clastogenic damage in the bone marrow (micronucleus induction and sister-chromatid exchanges) after animal treatment at very high, toxic doses, it appears to have marginal clastogenic effects at doses in the range of 5-10 mg/kg as employed in the present study (33, 59, 60) . Of the tissues examined for mutagenesis in our study, the spleen was the only one, in addition to the liver, for which consistent evidence of a small mutagenic effect was obtained. Small (Ͻ2-fold) but statistically significant increases in spleen MF were observed 7 days after 5 mg/kg and 28 days after 10 mg/kg NDMA, while a small increase which just failed to reach statistical significance was also observed 28 days after the end of 10 daily administrations of 1 mg/kg NDMA. Although examination of larger groups of animals would be required to obtain conclusive support for the significance of such small increases in MF, their consistent occurrence after all three dosing regimens and only in this tissue suggests that NDMA may indeed have a mutagenic effect on the spleen, despite the accumulation in this tissue of~40-100-fold fewer adducts than in the liver. We note that the spleen is particularly susceptible to methylating agent mutagenesis, exhibiting the highest levels of mutagenesis after administration of a single dose of MNU, a direct-acting methylating agent which, in contrast to NDMA, causes significant methylation in many tissues, including the spleen (61).
Our observations on the spectrum of spontaneous mutations in the liver of lacZ transgenic mice confirm and extend those reported by Douglas et al. (62) . Based on a total of 47 mutations sequenced, we found that GC→AT transitions are the most frequent spontaneous mutations, a large proportion of them being concentrated at CpG dinucleotides. We also observed all the other possible single-base substitutions, as well as a substantial number of frameshift mutations, including eight single-base and two larger deletions and three insertions.
We sequenced 47 liver mutations isolated 28 days after treatment with a single dose of 10 mg/kg NDMA, a treatment which resulted in a 3.6-fold increase in MF. Correction of the observed mutation spectrum for the likely contribution of spontaneous mutagenesis revealed that NDMA induced mainly GC→AT transitions (~60%) and deletions. Sequencing of a limited number of liver mutations induced in lacI transgenic mice by five daily doses of 4 mg/kg NDMA was reported to reveal 8/10 GC→AT transitions, one TA→GC transversion and one single-base insertion (35) . The proportion of GC→AT mutations obtained by us from the analysis of a much larger number of mutations is comparable to that reported above, as well as that caused by MNU in mammalian cells (29, (63) (64) (65) , and reflects the important role of direct miscoding by O 6 -meG during DNA replication. On the other hand, this proportion is significantly lower than that observed in E.coli in vitro or in combined in vivo/in vitro systems (30, 32, 35) , a difference which may reflect the high probability of conversion into mutations of a short-lived, highly mutagenic lesion such as O 6 -meG in rapidly proliferating bacterial cells. Approximately 63% of GC→AT mutations observed in our study were at 5ЈGpG sites, in agreement with the known sequence specificity of S N 1-type methylating agents (64, 65) .
The finding that approximately one third of NDMA-induced mutations involved deletion of one or more bases is unexpected. While the confounding of the mutation spectrum in NDMAtreated animals by spontaneous mutations does not permit the assignment of individual mutations to NDMA, it is statistically probable that most of the observed deletions of one or a few (up to 11) bases were caused by NDMA. As discussed above, the reported mutation spectrum of MNU in mammalian cells includes a significant proportion of non-GC→AT mutations. Furthermore, it has been noted that NDMA and its directacting analogue N-methyl-N-acetoxymethylnitrosamine appear to induce in E.coli non-GCϾAT mutations somewhat more frequently than MNU or MNNG (30, 32, 66) . However, such mutations consisted primarily of other types of single-base substitutions, deletions being exceedingly rare among them. The only case where a significant induction of deletions by MNU, MNNG and NDMA has been reported concerns mutagenesis in the vermillion gene of postmeiotic male germ cells of Drosophila melanogaster, where these methylating agents caused substantial numbers of deletions of a few to a few thousand base-pairs (but no single-base deletions) (67) . This observation demonstrates that, in the presence of appropriate host conditions, methylation damage of DNA includes lesions capable of leading to deletions. We note, in this respect, that we have recently observed that the methylating cancer chemotherapeutic drug procarbazine also causes a substantial number of small deletions in the bone marrow of λlacZ transgenic mice (68) . Some methylated DNA adducts (especially N3-methyladenine, but also O 6 -meG) can act as full or partial blocks of DNA replication (69), thus possibly leading to strand misalignment and consequent deletions, especially small deletions. It is also possible that base excision repair of lesions at ring nitrogens (including the abundant adduct N7-meG) might give rise to deletions if not properly completed (70) . Another possibility is that abortive mismatch repair of O 6 -meG:T pairs through repeated cycles of excision and resynthesis of the strand opposite the adduct (71, 72) , believed to be primarily a cause of cell death, may also act as a source of deletions in surviving cells. Finally, it is possible that NDMA may generate one or more genotoxic intermediates different from that produced by MNU, something for which there exists additional evidence (73, 74) . One such possible metabolite is formaldehyde produced in situ during the oxidative metabolism of NDMA. Formaldehyde is known to damage DNA, inducing primarily protein-DNA crosslinks which can give rise to deletions or other major changes in the DNA sequence (75, 76) . Indeed, formaldehyde causes, in addition to base substitutions, large deletions and insertions (77, 78) , and there is evidence that their relative proportions can vary depending on the dose employed. It is important to have in mind, in this respect, that during NDMA's metabolism formaldehyde is produced in equimolar proportion to the methylating intermediate within the cell and in close proximity to the nucleus. Evidence that formaldehyde produced during metabolism may mediate mutagenicity has recently been provided for another chemical, methylene chloride (79) .
Summarising, we have found that the extent of NDMAinduced mutagenesis in mouse liver increases disproportionately to dose intensity and to DNA adduct induction in the dose region 1-10 mg/kg. This suggests that toxicity-induced liver cell proliferation may play an important role in determining NDMA mutagenesis in the liver and that extrapolation of NDMA-mediated mutagenic effects to low dose levels should not be based on the assumption of dose linearity, even if dose is expressed in terms of DNA damage. At the highest dose examined (10 mg/kg), in addition to GC→AT mutations, NDMA induces a significant proportion of deletions of one or a few bases. The elucidation of the molecular mechanism of these mutations may assist in the interpretation of mutation spectra in cancer genes of human cancers in whose etiology a possible role of NDMA is suspected.
